We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
-6.84%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$23.1B
AUM Growth
-$3.48B
Cap. Flow
-$129M
Cap. Flow %
-0.56%
Top 10 Hldgs %
80.48%
Holding
138
New
11
Increased
23
Reduced
15
Closed
12

Top Buys

Rank Stock Value
1
TLIS
Talis Biomedical Corporation Common Stock
TLIS
+$126M
2
IMCR icon
Immunocore
IMCR
+$112M
3
GBT
Global Blood Therapeutics, Inc.
GBT
+$106M
4
TIL icon
Instil Bio
TIL
+$99.9M
5
DSGN icon
Design Therapeutics
DSGN
+$48.5M

Top Sells

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$737M
2
KRRO icon
Korro Bio
KRRO
+$31.1M
3
ADPT icon
Adaptive Biotechnologies
ADPT
+$22.5M
4
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$13M
5
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$11.4M

Sector Composition

Rank Sector Weight
1 Healthcare 97.05%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SGEN
1
DELISTED
Seagen Inc. Common Stock
SGEN
$6.56B 28.46%
47,270,759
+1,335
+0% +$215K
ONC
2
BeOne Medicines Ltd
ONC
$33.9B
$4.06B 17.61%
11,668,897
– –
INCY icon
3
Incyte
INCY
$25.3B
$2.6B 11.28%
32,001,387
+1,646
+0% +$140K
KOD icon
4
Kodiak Sciences
KOD
$2.44B
$1.57B 6.82%
13,879,952
– –
ACAD icon
5
Acadia Pharmaceuticals
ACAD
$4.45B
$1.08B 4.69%
41,910,704
+6,118
+0% +$269K
ALXN
6
DELISTED
Alexion Pharmaceuticals
ALXN
$611M 2.65%
3,993,312
-4,767,482
-54% -$737M
NVTA
7
DELISTED
Invitae Corporation
NVTA
$602M 2.61%
15,749,182
+100,000
+0.6% +$4.55M
BMRN icon
8
BioMarin Pharmaceuticals
BMRN
$11.9B
$573M 2.48%
7,589,294
– –
ASND icon
9
Ascendis Pharma A/S
ASND
$16.5B
$456M 1.98%
3,540,270
– –
PRLD icon
10
Prelude Therapeutics
PRLD
$359M
$439M 1.9%
10,123,824
+5,188
+0.1% +$344K
ABCL icon
11
AbCellera Biologics
ABCL
$1.63B
$355M 1.54%
10,450,180
– –
ARGX icon
12
argenx
ARGX
$54.9B
$308M 1.34%
1,119,557
+100,000
+10% +$31.6M
IGMS
13
DELISTED
IGM Biosciences
IGMS
$242M 1.05%
3,156,102
+11,210
+0.4% +$1.02M
MRTX
14
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$241M 1.05%
1,409,784
– –
MDGL icon
15
Madrigal Pharmaceuticals
MDGL
$12.4B
$175M 0.76%
1,499,213
– –
AMRN
16
Amarin Corp
AMRN
$300M
$164M 0.71%
1,322,671
-76,917
-5% -$10.3M
GBT
17
DELISTED
Global Blood Therapeutics, Inc.
GBT
$131M 0.57%
3,217,441
+2,297,066
+250% +$106M
BCRX icon
18
BioCryst Pharmaceuticals
BCRX
$2.44B
$129M 0.56%
12,710,818
+15,000
+0.1% +$155K
IMCR icon
19
Immunocore
IMCR
$1.68B
$107M 0.47%
+2,520,730
New +$112M
PACB icon
20
Pacific Biosciences
PACB
$432M
$107M 0.46%
3,201,972
– –
TIL icon
21
Instil Bio
TIL
$49.2M
$97.7M 0.42%
+194,685
New +$99.9M
TLIS
22
DELISTED
Talis Biomedical Corporation Common Stock
TLIS
$97.3M 0.42%
+504,989
New +$126M
HRTX icon
23
Heron Therapeutics
HRTX
$92.5M
$97.2M 0.42%
5,994,704
– –
CERS icon
24
Cerus
CERS
$575M
$82.4M 0.36%
13,713,195
– –
ALLK
25
DELISTED
Allakos
ALLK
$80.7M 0.35%
703,050
-11,200
-2% -$1.41M
1
2 3 4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q1 2021 Portfolio in Review

As of Q1 2021, Baker Bros. Advisors held 138 positions worth $23.1B, down 13% from $26.5B the previous quarter. Its ten largest holdings account for 80% of the portfolio.

Baker Bros. Advisors's Q1 2021 filing shows 11 new, 23 increased, 15 reduced and 12 closed positions. Its largest new stake was Talis Biomedical Corporation Common Stock: 504,989 shares worth $97.3M. The largest sale was Alexion Pharmaceuticals, an estimated $737M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 97% a quarter earlier, followed by Financials.

  • Baker Bros. Advisors's largest Q1 2021 buy was Talis Biomedical Corporation Common Stock: 504,989 shares worth $97.3M.
  • Baker Bros. Advisors added most to Global Blood Therapeutics, Inc. in Q1 2021, an estimated $106M increase.
  • Baker Bros. Advisors's biggest Q1 2021 reduction was Alexion Pharmaceuticals, cutting an estimated $737M.
  • Baker Bros. Advisors fully exited Adaptive Biotechnologies in Q1 2021, selling an estimated $22.5M.
  • Baker Bros. Advisors's ten largest holdings make up 80% of its $23.1B portfolio in Q1 2021.
  • Baker Bros. Advisors opened 11 new positions and closed 12 in Q1 2021.
  • Baker Bros. Advisors's portfolio value fell 13% quarter-over-quarter to $23.1B.

Based on Baker Bros. Advisors's 13F filing for Q1 2021, filed 17 May 2021.